All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Checkpoint Inhibitors, FGFR Inhibitors Lead to Continued Advancements in Biliary Tract Cancer

February 13th 2023

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

TKI/Immunotherapy Combinations Expand RCC Treatment Options

February 12th 2023

Rohit Kumar, MD, discusses the benefits of TKI/immunotherapy doublets in renal cell carcinoma, unmet needs regarding future research with triplet therapies in the frontline setting, and how hypoxia inducible factor inhibitors may play a role in the treatment of patients who have progressed on prior TKI/immunotherapy combinations.

Characterization of Relapse-Defining Events Through Patient Evaluation and Advanced Imaging Improves Treatment Selection in Multiple Myeloma

February 11th 2023

Matthew Brunner, MD, discusses how key patient factors, the use of advanced imaging modalities, and the relationship between community and academic centers influence treatment approaches in relapsed/refractory multiple myeloma.

Results of the SORAYA Study Show Conjugate Therapy Produced Remissions in One-third of Patients With Drug-Resistant Ovarian Cancer

February 10th 2023

In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.

FDA Places Partial Clinical Hold on VELA Trial With BLU-222 in Advanced Solid Tumors

February 10th 2023

The FDA has placed a partial clinical hold on the phase 1/2 VELA trial due to visual adverse effects observed in select patients who received the investigational treatment BLU-222.

NCCN Launches Health Equity Report Card to Address Racial Disparities in Cancer Care

February 10th 2023

The National Comprehensive Cancer Network has partnered with the American Cancer Society Cancer Action Network and the National Minority Quality Forum to launch the new Health Equity Report Card pilot program to address structural and interpersonal bigotry that results in disparities in cancer care and outcomes.

Ide-cel Improves PFS vs SOC in Relapsed/Refractory Multiple Myeloma

February 10th 2023

Idecabtagene vicleucel improved progression-free survival compared with standard combination regimens in patients with relapsed/refractory multiple myeloma after 2 to 4 prior lines of therapy and who were refractory to their last regimen, according to results from the phase 3 KarMMa-3 trial.

Powerful AI Algorithm Provides New Insights into Deadly Glioblastoma and Other Cancers

February 10th 2023

An international research group, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has developed a new machine learning algorithm that can combine large datasets from multiple sources to pinpoint kinases and potentially target them for treatment.

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10th 2023

The combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carcinoma.

Multifaceted Approach Remains a Linchpin for Stage IIIB NSCLC Therapy

February 10th 2023

Although emerging strategies are expanding options for treating patients with early-stage non–small cell lung cancer, stage IIIB disease continues to pose challenges. A multimodality approach may help overcome current barriers to care.

Encorafenib/Cetuximab Plus Chemo Viable for Continued Study in BRAF V600E–Mutated mCRC

February 10th 2023

Scott Kopetz, MD, discussed the key objectives of the phase 3 BREAKWATER trial being done in patients with BRAF V600E–mutated mCRC, the recently reported safety and efficacy data observed with encorafenib plus cetuximab and chemotherapy, and the importance of conducting biomarker research to further personalize treatment in these patients.

ODAC Votes in Favor of Continued Development of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer

February 9th 2023

In an 8 to 5 vote, the FDA’s ODAC voted that data from two proposed single-arm trials will provide adequate means of characterizing the risk-benefit profile of dostarlimab for the treatment of patients with dMMR/MSI-H locally advanced rectal cancer.

FDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer

February 9th 2023

The FDA has granted a regular approval to dostarlimab-gxly (Jemperli) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

Biomarkers Clarify Treatment Decisions and Sequencing in Endometrial Cancer

February 9th 2023

Emma L. Barber, MD, emphasized the importance of the ongoing phase 3 PORTEC-4a trial, which is investigating the role of molecular risk profiles in determining whether patients with endometrial cancer should receive no adjuvant therapy, vaginal brachytherapy, or external beam radiotherapy.

Encorafenib Plus Cetuximab With Nivolumab Under Investigation in BRAF V600E–Mutant mCRC

February 9th 2023

Investigators in the phase 2 SWOG S2107 trial are evaluating encorafenib plus cetuximab and nivolumab for patients with previously treated, microsatellite stable, unresectable, or metastatic colorectal cancer harboring a BRAF V600E mutation.

Development of Seribantumab for NRG1+ Advanced Solid Tumors Put On Hold

February 9th 2023

Elevation Oncology is pausing development of the human anti–HER3 IgG2 monoclonal antibody seribantumab, along with the phase 2 CRESTONE trial investigating the agent, in patients with advanced solid tumors harboring NRG1 fusions.

Bringing Cancer Treatment Opportunities to Communities Across Georgia Where Care May Not Be Available

February 9th 2023

Multiple teams working inside the Georgia Cancer Center at the Medical College of Georgia at Augusta University are committed to closing care gaps across Georgia.

Brexucabtagene Autoleucel Elicits OS Benefit in Relapsed/Refractory B-ALL

February 9th 2023

The CAR T-cell therapy brexucabtagene autoleucel produced a median overall survival of 26 months in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma

February 9th 2023

Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.

Herbst Highlights the Implications of the FDA Approval of Adjuvant Pembrolizumab in NSCLC

February 9th 2023

Roy S. Herbst, MD, PhD, discussed the data that supported the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer, highlighted the implications of the approval for the paradigm, and outlined further research opportunities.